Skip to main content
. 2014 Oct 17;4(10):e252. doi: 10.1038/bcj.2014.72

Table 3. Comparison of adverse effect.

ALL202-U vs ALL97
Therapy G4 neutropenia (%) G3-G4 thrombocytopenia (%) Sepsis (%) G3-G4 hepatic toxicity (%) G3-G4 neuropathy (%)
ALL202-U (age 15–24)
 Induction     15 27.8 3.6
 Consolidation 99.2 97.8 7.4 13.5 2.4
 Sancturary 12 19.7 2.6 13.2 1.8
 Reinduction 65 42.6 3.9 16.7 0
 Reconsolidation 99 100 9.1 5.1 4
           
ALL97 (age 15–24)
 Induction     3.8 11.2 0
 C1 73.7 10.5 0 4.2 0
 C2 61.7 9.9 0 0 0
 C3 64.6 3.8 0 0 0
 C4 97.1 97.1 0 0 0
 C5 41.9 1.6 0 0 0
 C6 58.9 25 0 0 0
 C7 86.8 9.4 0 0 0
 C8 98 100 2.2 0 0
AYA vs pediatrics
Therapy Febrile neutropenia (%) G3-G4 pancreatitis (%) G4 hepatic toxicity (%) G3-G4 neuropathy (%)  
ALL202-U (age 15–24)
 Induction 46.5 6.6 1.0 3.6  
 Consolidation 44.4 0.0 0.0 2.4  
 Sancturary 9.7 0.0 0.0 1.8  
 Reinduction 25.5 5.8 1.0 0.0  
 Reconsolidation 55.6 0.0 0.0 4.0  
 Maintenance 0.8 0.3 0.3 0.2  
           
ALL-02-HR (age 10–18)
 Induction 63.9 5.0 3.4 9.3  
 Consolidation 58.0 1.1 3.5 6.5  
 Sancturary 37.8 0.0 0.0 13.3  
 Reinduction 51.8 1.1 1.1 3.3  
 Reconsolidation 73.7 0.0 0.0 0.0  
 Maintenance 8.5 0.3 0.6 0.2  

Abbreviation: AYA, adolescent and young adult.